Alzheimer's Drug Discovery Foundation
CompanyUnited StatesFounded 1998
Alzheimer's Drug Discovery Foundation develops one asset, in phase 1 (LX1001 in Alzheimer's disease). Mostly gene therapy acting on lipid and ceramide metabolism, proteostasis and APOE; based in the United States, founded in 1998.
- 1
- Asset
- Furthest stage
- Phase 1
- 0
- Trials
- 1
- Signal
Pipeline
1AAVrh10 gene therapy expressing human APOE2 to convert CSF phenotype in APOE4 homozygotes
Phase 1, Gene therapy, Lipid and ceramide metabolism, Proteostasis, Alzheimer's disease, early-onset Alzheimer's disease, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials3
- Signals6
- Similar companies6
Papers
Sex Hormone Therapies and Alzheimer's Disease: Prevention vs Treatment
AAIC 2025 abstract, 23 Dec 2025